A recently published scientific study from Lund University by lead researcher Charlotte Erlanson-Albertsson, MD, PhD found that subjects who were trying to lose weight and used the patented spinach extract Appethyl on a daily basis lost 43 percent more weight compared to those ingesting a placebo.
In this clinical trial, overweight women were given either a daily five gram dose of Appethyl or a control drink immediately before breakfast. Researchers found that the weight of the women ingesting Appethyl decreased significantly at 43 percent more than subjects ingesting the control drink.
This is one of three studies that also compared the effects of Appethyl after 90 days with those found after the first dose and found no decline of effects, indicating that Appethyl takes effect after the first dose and is just as effective after long-term use. One study showed that Appethyl reduced hunger by 25 percent four hours after consumption, in addition to reducing thoughts about food by 33 percent.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7426951-appethyl-spinach-extract/
SIRO Clinpharm, a leading full service clinical research organization, unveiled its new brand identity on Friday. The new look affirms the recent transformation in the company’s business strategy.
“With the vast experience garnered over the past 16 years, SIRO was set to take a leap forward. With its customer centric leadership, we have built depth in various areas of competencies, leveraging our 4 pillars – people, processes, technologies and solutions,” said Dr. Gautam Daftary, founder and chairman, SIRO Clinpharm.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58672-SIRO-Clinpharm-unveils-new-brand-identity
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Reproductive Medicine Associates of New Jersey (http://www.rmanj.com) today presented interim findings from its BEST (Blastocyst Euploid Selective Transfer) trial, the first well-controlled clinical trial comparing in vitro fertilization (IVF) pregnancy rates in a group of women receiving a single embryo transfer (SET) with comprehensive chromosome screening (CCS) with a group receiving traditional morphology-based double embryo transfer (DET). The findings were presented at the American Society for Reproductive Medicine 68th Annual Meeting in San Diego, October 20-24, 2012.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58883-rmanj-best-trial-results-ivf-pregnancy-rates-women-asrm-annual-meeting
The science of bionics helped the more than 1 million Americans with leg amputations take a giant step forward, as the Rehabilitation Institute of Chicago (RIC) revealed clinical applications for the world’s first thought-controlled bionic leg in this week’s New England Journal of Medicine. This innovative technology represents a significant milestone in the rapidly-growing field of bionics. Until now, only thought-controlled bionic arms were available to amputees.
To view Multimedia News Release, go to http://www.multivu.com/mnr/63339-rehabilitation-institute-of-chicago-first-thought-controlled-bionic-leg
Express Scripts clinical innovations saved its clients $45 billion in 2018 and delivered a 25-year record low drug trend of just 0.4 percent across employer-sponsored plans, according to data released today in its annual Drug Trend Report, an authoritative analysis of drug spending in the U.S.
Express Scripts’ solutions for driving lower drug prices and fostering the use of lower-net-cost treatments are making medication more accessible for beneficiaries. Unit drug costs decreased in 2018 for employer-sponsored and Medicare plans, while utilization of medications rose.
To view the multimedia release go to:
https://www.multivu.com/players/English/8478051-express-scripts-2018-drug-trend-report/
It’s inevitable that we’re all going to age, but Dr. Ronald Kaiser has discovered a way to make it enjoyable. In his new book Rejuvenaging: The Art and Science of Growing Older with Enthusiasm, Dr. Kaiser lays out the path to not only embracing our later years but making them the best half of our lives. Drawing on more than a half-century of clinical experience, and 80 years of living, Kaiser shares his simple plan to success. Find out more at http://www.thementalhealthgym.com/ Non-Fiction/Self Help
Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, commemorated its 50-year anniversary by awarding $150,000 in total grants to three organizations that share its goal to improve healthcare: The American Red Cross, the National Ovarian Cancer Coalition and Autism Speaks.
At a ceremony at the company’s flagship clinical laboratory in Teterboro, NJ, the company’s chairman, president and CEO Steve Rusckowski presented Health In Your Hands grants of $50,000 to representatives from each organization. Paul Brown, M.D., founder and former CEO of Quest’s predecessor company Metropolitan Pathology Laboratory, Inc. or MetPath, established in April, 1967, was also recognized at the event.
To view the multimedia release go to:
https://www.multivu.com/players/English/8080751-quest-diagnostics-50th-anniversary/
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, has announced additional positive data from its Phase 2 clinical trial of PV-10 for metastatic melanoma. The data, on changes in visceral and nodal metastases following chemoablation of cutaneous melanoma lesions with PV-10, was presented by Dr.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/pvct/43978/
Solta Medical, Inc. (Nasdaq: SLTM), a global leader in the medical aesthetics market and manufacturer of the industry's three premier brands: Thermage®, Fraxel®, and Isolaz®, is pleased to announce that it has partnered with PGA TOUR golfer Scott McCarron to raise awareness about skin protection and the Fraxel re:store® laser treatment. As the leader in fractional laser technology, Fraxel delivers minimally invasive clinical solutions to resurface aging and sun damaged skin, including the removal of actinic keratoses (AK’s ) — a precancerous skin condition caused by sun exposure. Fraxel re:store treatment provides superior results for AKs on the face or other areas of the body displaying the signs of photodamage.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/solta/45388/
Interim clinical results from Project IMPACT: Diabetes, announced today by the American Pharmacists Association (APhA) Foundation, show statistically significant decreases in A1C or blood sugar levels, LDL cholesterol, systolic blood pressure and Body Mass Index (BMI), which are all recognized standards of diabetes care. Participating patients in 25 communities who experienced improved outcomes encompass almost every socioeconomic class, insurance status and ethnicity.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62268-american-pharmacists-association-apha-foundation-project-impact-diabetes
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
